April 1, 2021
J&J answers allegations over vaccine problems
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Author
April 1, 2021
FDA approves Sanofi’s Sarclisa to treat relapsed multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the…
March 31, 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA’s human medicines committee (CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines…
March 31, 2021
GSK to support manufacture of Novavax’ COVID-19 vaccine
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up…
March 29, 2021
CHMP recommends Novo Nordisks’s Saxenda for the treatment of obesity in adolescents
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use…
March 29, 2021
FDA approves new indication for Astellas Pharma’s bladder dysfunction drug
The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
March 25, 2021
Scientists find evidence that novel coronavirus infects the mouth’s cells
An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth.…
March 25, 2021
AstraZeneca answers accusation to stockpiling vaccines; 13M doses for COVAX, 16M for Europe
AstraZeneca has denied accusations of stockpiling vaccines stating that the process of manufacturing vaccines is very complex and time consuming…
March 23, 2021
Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual Meeting Reinforce the Efficacy and Safety of Isturisa® (osilodrostat) in Cushing’s Disease
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation…
March 22, 2021
VeriSIM Life launches PulmoSIM Therapeutics to Develop Treatments for Rare Respiratory Diseases
SAN FRANCISCO–(BUSINESS WIRE)–#artificialintelligence–Today, VeriSIM Life (VeriSIM) announces the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to…